In conclusion, this study presents strong evidence supporting the adoption of anti-IL1β treatment strategies for patients with prostate cancer to be combined with AR-targeted therapies, which could address both ARNEG and AR-inactivated tumor phenotypes that emerge due to current standard of care, thereby increasing the likelihood of curative outcomes. The gene discussed is AR; the disease is prostate carcinoma.